Search clinical trials for: low-grade B-cell lymphoma

Total 11026 results

Celgene

Recruiting

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Lymphoma Nonhodgkin

Japan
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Lymphoma, B-Cell

Japan
Biogen

Completed

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

United States, Canada
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma (CD19-CARNK/T)

Mantle Cell Lymphoma (MCL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | Diffuse Large B Cell Lymphoma( DLBCL)
Koo Foundation Sun Yat-Sen Cancer Center

Recruiting

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma (PentixaFor)

Indolent B-Cell Non-Hodgkin Lymphoma

Taiwan
Abramson Cancer Center at Penn Medicine
Genmab

Not yet recruiting

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Lymphoma, Non-Hodgkin | High-grade B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Relapsed Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Zumutor Biologics Inc.

Recruiting

Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Colorectal Cancer | Esophageal Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Pancreas Adenocarcinoma | Diffuse Large B Cell Lymphoma | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Biliary Tract Cancer | High Grade Ovarian Serous Adenocarcinoma

United States
Juventas Cell Therapy Ltd.

Not yet recruiting

Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

B-cell Acute Lymphoblastic Leukemia
Rong Tao
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia With Failed Remission

China
InSilico Medicine Hong Kong Limited

Recruiting

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Advanced Solid Tumors | Relapsed/Refractory B-cell Lymphoma

China
Ruijin Hospital

Not yet recruiting

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Diffuse Large B-Cell Lymphoma
University of Washington

Not yet recruiting

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal Zone Lymphoma and other conditions

United States
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Diffuse Large B Cell Lymphoma

Spain
Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

B Cell Lymphoma

China
Sun Yat-sen University

Not yet recruiting

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Primary Mediastinal Large B Cell Lymphoma
Tianjin Medical University Cancer Institute and...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | B-Cell Non-Hodgkin Lymphoma-Refractory

China
Merck Sharp & Dohme LLC

Not yet recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Burkitt Lymphoma | Ewing Sarcoma | Neuroblastoma | Diffuse Large B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia
Arvinas Inc.

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

United States, Spain
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Dren Bio
Novotech (Australia) Pty Limited

Recruiting

A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin Lymphoma

Australia, Hong Kong, Korea, Republic of, Singapore, Taiwan
Beijing GoBroad Hospital

Not yet recruiting

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
Mayo Clinic

Recruiting

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin Lymphoma

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Large B-cell Lymphoma

China
Ruijin Hospital

Not yet recruiting

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-NHL, Extranodal, TP53 Alterations, Bulky Mass
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
Celgene

Recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

Korea, Republic of, Canada, United States, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Japan, Malaysia, Mexico, New Zealand, Norway, Polan... and more
Sohag University

Not yet recruiting

Maintenance Hormonal Therapy and DLBCL

Diffuse Large B Cell Lymphoma
University Hospital, Montpellier

Recruiting

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? (CARTROG)

Diffuse Large B Cell Lymphoma

France
H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Indolent B-cell Lymphoma
Baylor College of Medicine

Not yet recruiting

CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) (CASEY)

Lymphoma | Leukemia, Myeloid, Acute | Leukemia, T-Cell | Leukemia, B-cell

United States
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Paolo Corradini
Annalisa Chiappella; Cristiana Carniti; Anna Dodero

Recruiting

Italian Observational Study on CAR-T Therapy for Lymphoma (CART-SIE)

Follicular Lymphoma | Mantle Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Low Grade B-Cell Lymphoma

Italy
Stanford University
The Leukemia and Lymphoma Society

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Hairy Cell Leukemia

United States
Beijing GoBroad Hospital

Not yet recruiting

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia
Leuko Labs, Inc.

Not yet recruiting

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia (PC002)

Multiple Myeloma | Diffuse Large B Cell Lymphoma
Chinese PLA General Hospital

Recruiting

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Non-hodgkin Lymphoma

China
Sinocelltech Ltd.

Not yet recruiting

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, B-cell

China
Guangdong Ruishun Biotech Co., Ltd
Ruijin Hospital; Southern Medical University, China; Beijing GoBroad Hospital

Not yet recruiting

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

B-cell Non-Hodgkin's Lymphoma
Peking University Cancer Hospital & Institute
Nanjing Legend Biotech Co.

Recruiting

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed B-cell Non-Hodgkin Lymphoma | Refractory B-cell Non-Hodgkin Lymphoma

China
Incyte Biosciences Italy S.r.l
Advice Pharma Group srl

Recruiting

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

DLBCL - Diffuse Large B Cell Lymphoma

Italy
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

China
Second Affiliated Hospital, School of Medicine,...
Ningbo Medical Center Lihuili Hospital; Huizhou Municipal Central Hospital; Taizhou... and other collaborators

Recruiting

Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI

Diffuse Large B-cell Lymphoma

China
University of Alabama at Birmingham

Not yet recruiting

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Lymphoma, Follicular | Lymphoma, B-Cell | Diffuse Large B Cell Lymphoma

United States

Search clinical trials for: low-grade B-cell lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations